July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Sustained oral delivery of ticagrelor (Brilinta) protects against retinal degeneration
Author Affiliations & Notes
  • Wennan Lu
    Anatomy & Cell Biology, Univ of Pennsylvania, Sch of Dental Med, Philadelphia, Pennsylvania, United States
  • Keith Campagno
    Anatomy & Cell Biology, Univ of Pennsylvania, Sch of Dental Med, Philadelphia, Pennsylvania, United States
  • Leif Carlsson
    AstraZeneca, Sweden
  • Claire H Mitchell
    Anatomy & Cell Biology, Univ of Pennsylvania, Sch of Dental Med, Philadelphia, Pennsylvania, United States
    Ophthalmology, University of Pennsylvania, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Wennan Lu, None; Keith Campagno, None; Leif Carlsson, AstraZeneca (E); Claire Mitchell, AstraZeneca (F), Self (P)
  • Footnotes
    Support  Support: NH Grant EY013434, AstraZeneca.
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 49. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Wennan Lu, Keith Campagno, Leif Carlsson, Claire H Mitchell; Sustained oral delivery of ticagrelor (Brilinta) protects against retinal degeneration. Invest. Ophthalmol. Vis. Sci. 2019;60(9):49.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Effective treatment of chronic retinal degenerations will require a strategy that is well tolerated in elderly patients and safe; the use of FDA approved drugs may provide an accelerated pathway to development. We have previously demonstrated that the P2Y12 receptor antagonist ticagrelor (Brilinta) restored lysosomal acidity and reduced autofluorescence in compromised RPE cells from ABCA4-/- mice. Here we tested whether oral delivery of ticagrelor can actually preserve vision in ABCA4-/- mice.

Methods : Albino ABCA4-/- mice were fed 0.1-0.15% ticagrelor in their chow for 1.5-7 months, with control mice using normal chow. As this mouse model shows minimal photoreceptor damage, a moderate light exposure regime of 4 hrs in 10,000 lux white light was used to enhance retinal degeneration. Retinal function was determined with electroretinogram (ERG) recordings. Photoreceptor survival was determined by evaluating outer nuclear layer (ONL) thickness with optical coherence tomography (OCT) and counting nuclei in the ONL using histological sections.

Results : Addition of ticagrelor to chow was associated with protection of photoreceptors after light exposure. The a- and b-wave ERG recordings at intensities of 0.1 and 1.0 cd.s/m2 were significantly greater in the ticagrelor-treated mice. This difference in a- and b- wave performance was present 1, 7 and 14 days after exposure to light, implying a permanent protection. OCT measurements showed the thickness of the ONL was greater in mice treated with ticagrelor than in the untreated mice after light exposure. These OCT findings were supported by histological examination, with the number of surviving photoreceptor nuclei greater in mice treated with ticagrelor than control. Chronic treatment with ticagrelor appeared safe in mice exposed to normal light levels, as mice treated for 7 months showed no difference in thickness of the ONL or changes in the fundus appearance as compared to untreated controls.

Conclusions : These observations identify inhibition of the P2Y12 receptor as a useful target in protecting photoreceptor function in retinal degeneration. Ticagrelor was previously shown to low lysosomal pH and increase degradation of lysosomal waste in these mice, suggesting protection is associated with lysosomal stabilization. As Brilinta is widely used in the aged population, these results may identify a useful target for treatment of age-related retinal degenerations.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×